Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 11/20 | 1.00 |
| ▸ | HSD17B2 | P37059 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | BCR | P11274 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8050006 | 0.97 | HSD17B1 (0.94) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL2682114 | 0.95 | HSD17B1 (0.90) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL29832647 | 0.95 | HSD17B1 (0.90) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL29404406 | 0.95 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL1180998 | 0.95 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL70625 | 0.95 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL7129229 | 0.95 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL29551999 | 0.94 | HSD17B1 (0.88) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL69369 | 0.94 | HSD17B1 (0.88) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| Hydrogen Sulfide SCHEMBL23879303 | 0.92 | HSD17B1 (0.95) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046147-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES | UNIVERSITAT DES SAARLANDES (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046147-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES | UNIVERSITAT DES SAARLANDES (DE) | 2011-02-24 | — | — | US | disclosed |
| WO-2009027346-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2009-03-05 | — | — | WO | disclosed |
| US-6187494-B1 | AROMATIC POLYCARBONATE INCLUDING POLYPHENYLENE ETHER PORTIONS; WEAR RESISTANCE | RICOH COMPANY, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046147-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES | HSD17B1, HSD17B11, HSD17B2 | HSD17B1 1/4885HSD17B2 3/4885CYP3A4 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.